溶血指标联合监测在淋巴瘤相关噬血细胞综合征继发Evans综合征疗效评估中的价值-附1例报告及文献复习

敖正才 ,  王慧 ,  徐玉霞

中国输血杂志 ›› 2026, Vol. 39 ›› Issue (6) : 789 -794.

PDF (2925KB)
中国输血杂志 ›› 2026, Vol. 39 ›› Issue (6) : 789 -794. DOI: 10.13303/j.cjbt.issn.1004-549x.2026.06.013
论著

溶血指标联合监测在淋巴瘤相关噬血细胞综合征继发Evans综合征疗效评估中的价值-附1例报告及文献复习

作者信息 +

Value of combined monitoring of hemolytic reaction indicators in efficacy assessment of lymphoma-associated hemophagocytic lymphohistiocytosis secondary to Evans syndrome: a case report and literature review

Author information +
文章历史 +
PDF (2994K)

摘要

目的 探讨溶血指标联合监测在淋巴瘤相关噬血细胞综合征(lymphoma-associated hemophagocytic lymphohistiocytosis, LA-HLH)继发 Evans 综合征(Evans syndrome, ES)疗效评估中的价值。方法 纳入 1 例 LA-HLH 继发 ES 并发生溶血危象的患者,在患者因重度贫血接受必要红细胞输注的前提下,对输血后血红蛋白(hemoglobin, Hb)增幅、网织红细胞百分比(reticulocyte percentage, RET%)、总胆红素(total bilirubin, TBil)、乳酸脱氢酶(lactate dehydrogenase, LDH)及直接抗人球蛋白试验(direct antiglobulin test, DAT)等溶血反应指标进行联合动态监测,结合近 5 年文献,分析上述指标动态变化与免疫抑制治疗应答的关系。结果 在溶血危象期,患者连续 2 次红细胞输注后 24 h Hb 增幅均<10 g/ L,表现为无效输血;强化免疫抑制治疗后,连续 2 次输注后 Hb 增幅分别达+14 g/ L 和+15 g/ L,转为有效输血。 同期 RET%由峰值29. 32%降至12. 71%,LDH 及 TBil 同步改善。 将 Hb 增幅与 RET%动态变化趋势、DAT 结果联合解读,有助于区分免疫性溶血、噬血现象和骨髓衰竭在贫血中的相对权重。结论 在严格把握输血适应证和患者安全的前提下,对溶血指标进行联合动态监测,可为 LA-HLH 继发 ES 的疗效评估提供实时、客观的床旁辅助信息,对优化治疗调整节点具有一定临床价值。

Abstract

Objective To investigate the value of combined monitoring of hemolytic reaction indicators in the efficacy assessment of lymphomaassociated hemophagocytic lymphohistiocytosis (LAHLH) secondary to Evans syndrome (ES). Methods One patient with LAHLH secondary to ES complicated by hemolytic crisis was enrolled. Under the premise that necessary red blood cell transfusions were administered due to severe anemia, combined dynamic monitoring was performed for the following hemolytic reaction indicators:posttransfusion hemoglobin increment, reticulocyte percentage (RET%), total bilirubin(TBil), lactate dehydrogenase (LDH), and direct antiglobulin test (DAT). Furthermore, based on the literature of the past five years, we analyzed the relationship between the dynamic changes of the these indicators and the response to immunosuppressive therapy. Results During the hemolytic crisis period, the 24hour posttransfusion hemoglobin increments were both <10 g/ L after two consecutive red blood cell transfusions, indicating ineffective transfusion. After intensified immunosuppressive therapy, the hemoglobin increments reached +14 g/ L and +15 g/ L, respectively, after two subsequent transfusions, converting to effective transfusion. Concurrently, RET% decreased from a peak of 29. 32% to 12. 71%, and LDH and bilirubin improved synchronously. The combined interpretation of hemoglobin increment, dynamic RET% trends, and DAT results facilitated the distinction of the relative contributions of immune hemolysis, hemophagocytosis, and bone marrow failure to anemia. Conclusion Under the strict premise that transfusion indications are adhered to and patient safety is ensured,,combined dynamic monitoring of hemolytic reaction indicators can provide realtime, objective bedside auxiliary information for the efficacy assessment of LAHLH secondary to ES, and has certain clinical value in optimizing the timing of treatment adjustments.

关键词

噬血细胞综合征 / 埃文斯综合征 / 溶血反应 / 疗效评估 / 网织红细胞

Key words

hemophagocytic lymphohistiocytosis / Evans syndrome / hemolytic reaction / efficacy assessment / reticulocyte

引用本文

引用格式 ▾
敖正才,王慧,徐玉霞. 溶血指标联合监测在淋巴瘤相关噬血细胞综合征继发Evans综合征疗效评估中的价值-附1例报告及文献复习[J]. 中国输血杂志, 2026, 39(6): 789-794 DOI:10.13303/j.cjbt.issn.1004-549x.2026.06.013

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

HENTER J I . Hemophagocytic lymphohistiocytosis[J].N Engl J Med, 2025, 392(6):584-598.

[2]

孙钰昆, 王昭. 噬血细胞综合征诊断研究进展[J].中国实用内科杂志, 2025, 45(4):330-335.

[3]

SUN Y K, WANG Z. Advances in diagnosis of hemophagocytic syndrome[J].Chin J Pract Intern Med, 2025, 45(4):330-335.

[4]

张连生, 邵宗鸿, 王化泉,等. EVANS 综合征诊断和治疗中国专家共识(2024 年版)[J].中华血液学杂志, 2024, 45(9):809-815.

[5]

ZHANG L S, SHAO Z H, WANG H Q, et al. Chinese expert consensus on the diagnosis and treatment of evans syndrome(2024)[J].Chin J Hematol, 2024, 45(9): 809-815.

[6]

张连生, 刘玉梅, 王化泉. 《EVANS 综合征诊断和治疗中国专家共识(2024 年版)》解读[J].临床血液学杂志, 2024, 37(11):762-765.

[7]

ZHANG L S, LIU Y M, WANG H Q, et al. Interpretation of chinese expert consensus on the diagnosis and treatment of evans syndrome(2024)[J].J Clin Hematol,2024,37(11):762-765.

[8]

FATTIZZO B, GURNARI C, BARCELLINI W, et al. Diagnosis and management of Evans syndrome in adults: first consensus recommendations[J].Lancet Haematol, 2024,11(8):e617-e628.

[9]

LA ROSEE P, HORNE A C, HINES M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults[J].Blood, 2019, 133(23): 2465-2477.

[10]

CRODEN J, GROSSMAN J, SUN H. External validation of the hlh-2004 diagnostic criteriaand h-score for diagnosis of hemophagocytic lymphohistiocytosis in adults[J].BLOOD, 2020, 136(SUPPL 1):44-45.

[11]

HENTER J I, HORNE A, ARICO M, et al. HLH-2004:Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J].Pediatr Blood Cancer, 2007, 48(2):124-131.

[12]

临床输血规范流程协作组,李志强. 临床输血适应性与有效性评价流程[J].中国输血杂志,2013,26(6): 587-589.

[13]

LI Z Q. Clinical transfusion appropriateness and efficacy evaluation process[J].Chin J Blood Transfusion, 2013, 26(6):587-589.

[14]

HENTER J I, SIENI E, ERIKSSON J, et al. Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited[J].Blood, 2024, 144(22):2308-2318.

[15]

郭路瑶, 马艳萍, 侯晓旭, 等. 淋巴瘤相关噬血细胞综合征的临床特征及预后分析[J].肿瘤研究与临床, 2025, 37(4):280-285.

[16]

GUO L Y, MA Y P, HOU X X, et al. Clinical features and prognosis analysis of lymphoma-associated hemophagocytic lymphohistiocytosis[J].Cancer Res Clin,2025, 37(4):280-285.

[17]

HAYDEN A, PARK S, GIUSTINI D, et al. Hemophagocytic syndromes (HPSS) including hemophagocytic lymphohistiocytosis (HLH) in adults:a systematic scoping review[J].Blood Rev, 2016, 30(6):411-420.

[18]

JACOBS J W, RAZA S, CLARK L M, et al. Mixed autoimmune hemolytic anemia:a systematic review of epidemiology, clinical characteristics, therapies, and outcomes[J].Am J Hematol, 2025, 100(8):1397-1407.

[19]

滕光英, 屈文静, 王莺,等. 血液肿瘤合并继发性噬血细胞综合征患儿的临床特征及预后分析[J].中国实验血液学杂志, 2025, 33(6):1809-1813.

[20]

TENG G Y, QU W J, WANG Y, et al. Clinical characteristics and prognosis of children with hematolog-ical malignancies complicated by secondary hemophagocytic lymphohistiocytosis[J].J Exp Hemato, 2025, 33(6):1809-1813.

[21]

CHEN C, WANG L, HAN B, et al. Autoimmune hemolytic anemia in hospitalized patients: 450 patients and their red blood cell transfusions[J].Medicine (Baltimore). 2020, 99(2):E18739.

[22]

HILL Q A, STAMPS R, MASSEY E, et al. The diagnosis and management of primary autoimmune haemolytic anaemia[J].Br J Haematol,2017, 176(3):395-411.

[23]

IRIMIA R, BARBU S, POPA C,et al. Evans syndrome as a possible complication of brentuximab vedotin therapy for peripheral t cell lymphoma[J].Hematol Rep, 2023, 15(1):220-224.

[24]

赵艾琳, 李萌, 李林峰, 等. 淋巴瘤相关噬血细胞综合征临床特征和预后分析[J].中华医学杂志, 2022, 102(28):2173-2180.

[25]

ZHAO A L, LI M, LI L F, et al. Clinical characteristics and prognosis of lymphomaassociated hemophagocytic syndrome[J].Natl Med J China, 2022, 102(28):2173-2180.

[26]

张雅丽, 郝静楠, 孙萌萌, 等. 继发性噬血细胞综合征病因、临床特点及预后分析[J].中国实验血液学杂志, 2024, 32(4):1230-1237.

[27]

ZHANG Y L, HAO J N, SUN M M, et al. Etiology, clinical characteristics and prognosis of secondary hemophagocytic syndrome[J].J Exp Hematol,2024, 32 (4):1230-1237.

AI Summary AI Mindmap
PDF (2925KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉